-
Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-13 Oliver A Cornely, Rosanne Sprute, Matteo Bassetti, Sharon C-A Chen, Andreas H Groll, Oliver Kurzai, Cornelia Lass-Flörl, Luis Ostrosky-Zeichner, Riina Rautemaa-Richardson, Gunturu Revathi, Maria E Santolaya, P Lewis White, Ana Alastruey-Izquierdo, Maiken C Arendrup, John Baddley, Aleksandra Barac, Ronen Ben-Ami, Adrian J Brink, Jan H Grothe, Jesus Guinea, Li-Ping Zhu
Candida species are the predominant cause of fungal infections in patients treated in hospital, contributing substantially to morbidity and mortality. Candidaemia and other forms of invasive candidiasis primarily affect patients who are immunocompromised or critically ill. In contrast, mucocutaneous forms of candidiasis, such as oral thrush and vulvovaginal candidiasis, can occur in otherwise healthy
-
Early evidence of RSV vaccination impact on hospitalisation rates of older people in Scotland Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-13 Safraj Shahul Hameed, Chris Robertson, Kirsty Morrison, Ross McQueenie, Jim McMenamin, Sam Ghebrehewet, Kimberly Marsh
No Abstract
-
Trump administration dismantles USAID Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-13 Talha Burki
No Abstract
-
President Trump orders US withdrawal from WHO Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-11 Cahal McQuillan
No Abstract
-
Virological characteristics of the SARS-CoV-2 LP.8.1 variant Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-10 Luo Chen, Yu Kaku, Kaho Okumura, Keiya Uriu, Yukun Zhu, Jumpei Ito, Kei Sato
No Abstract
-
Targeting the SARS-CoV-2 reservoir in long COVID Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-10 Amy D Proal, Soo Aleman, Morgane Bomsel, Petter Brodin, Marcus Buggert, Sara Cherry, Daniel S Chertow, Helen E Davies, Christopher L Dupont, Steven G Deeks, E Wes Ely, Alessio Fasano, Marcelo Freire, Linda N Geng, Diane E Griffin, Timothy J Henrich, Stephen M Hewitt, Akiko Iwasaki, Harlan M Krumholz, Michela Locci, Michael J Peluso
There are no approved treatments for post-COVID-19 condition (also known as long COVID), a debilitating disease state following SARS-CoV-2 infection that is estimated to affect tens of millions of people. A growing body of evidence shows that SARS-CoV-2 can persist for months or years following COVID-19 in a subset of individuals, with this reservoir potentially driving long-COVID symptoms or sequelae
-
Cash incentives as a bold new strategy for tuberculosis control Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-06 Norbert Ndjeka, Waasila Jassat
No Abstract
-
Effects of conditional cash transfers and pre-test and post-test tuberculosis counselling on patient outcomes and loss to follow-up across the continuum of care in South Africa: a randomised controlled trial Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-06 Nazir Ismail, Harry Moultrie, Judith Mwansa-Kambafwile, Andrew Copas, Alane Izu, Sizulu Moyo, Donald Skinner, Farzana Ismail, Lara Gosce, Shaheed V Omar, Ibrahim Abubakar, Shabir A Madhi
BackgroundEconomic and behavioural factors lead to poor outcomes in patients with tuberculosis. We investigated the effects of a package of interventions consisting of pre-test and post-test tuberculosis counselling with conditional cash transfers on patient outcomes in adults undergoing investigation for pulmonary tuberculosis. MethodsThis pragmatic, open-label, individual randomised controlled trial
-
-
Approaches to increase access to community-based infectious disease control for ethnically, racially, and religiously marginalised populations: a scoping review Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-05 Seth W M Epling, Annika M Bjork, Lucia Martinez Cruz, Margaret C Baker
Marginalised populations often have reduced access to infectious disease prevention interventions, and as a result of this and other socioeconomic factors, these populations are at a higher risk of disease. Here, we reviewed the literature of community-based interventions delivered at the individual level across multiple diseases, and focused on how to increase access to infectious disease interventions
-
Beyond mosquitoes and malaria—ivermectin in Africa Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-04 Felix Hammann, Marta F Maia
No Abstract
-
KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2 Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-04 Qian Wang, Ian A Mellis, Madeline Wu, Anthony Bowen, Carmen Gherasim, Riccardo Valdez, Jayesh G Shah, Lawrence J Purpura, Michael T Yin, Aubree Gordon, Yicheng Guo, David D Ho
No Abstract
-
Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial Lancet Infect Dis (IF 36.4) Pub Date : 2025-02-04 A Fabrice Somé, Anthony Somé, Emmanuel Sougué, Cheick Oumar W Ouédraogo, Ollo Da, S Rodrigue Dah, Frederic Nikièma, Tereza Magalhaes, Lyndsey I Gray, Will Finical, Greg Pugh, Paula Lado, Jenna C Randall, Timothy A Burton, Molly E Ring, Anna-Sophia Leon, McKenzie Colt, Fangyong Li, Kaicheng Wang, Martina Wade, Roch K Dabiré
BackgroundThe success of crucial vector control efforts in Africa (eg, long-lasting insecticide-treated nets [ITNs] and indoor residual spraying) are threatened by widespread insecticide resistance and insufficient effect on outdoor mosquito biting. Studies have shown that ivermectin, used for the treatment of parasitic diseases, can kill malaria vectors that feed on the blood of treated people and
-
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-31 Mehul S Suthar, Kelly E Manning, Madison L Ellis, Shilpi Jain, Kareem Bechnak, Jake Vander Velden, Farida Laboune, Amy R Henry, Sucheta Godbole, Sungjin Kim, Malaya K Sahoo, Isabel Paredes, Serena M Dib, Suha Kalash, Christelle Radi, Heather Hicks, Azaibi Tamin, Meredith Gardner, Nicole Bowen, Peter Cook, Alberto Moreno
No Abstract
-
COVID-19 versus influenza: the need to align policies with COVID-19 realities Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Yan Xie
No Abstract
-
The hospital and mortality burden of COVID-19 compared with influenza in Denmark: a national observational cohort study, 2022–24 Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Peter Bager, Ingrid Bech Svalgaard, Frederikke Kristensen Lomholt, Hanne-Dorthe Emborg, Lasse Engbo Christiansen, Bolette Soborg, Anders Hviid, Lasse S Vestergaard
BackgroundThe COVID-19 pandemic has been on a downward trend since May, 2022, but it continues to cause substantial numbers of hospital admissions and deaths. We describe this burden in the 2 years since May, 2022, and compare it with the burden of influenza in Denmark. MethodsThis observational cohort study included residents in Denmark from May 16, 2022, to June 7, 2024. Data were obtained from national
-
Maternal views on RSV vaccination during the first season of implementation in England and Scotland Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Thomas C Williams, Robin Marlow, Steve Cunningham, Simon B Drysdale, Helen Groves, Dalia Iskander, Xinxue Liu, Mark D Lyttle, Chengetai D Mpamhanga, Shaun O'Hagan, Thomas Waterfield, Damian Roland
No Abstract
-
Vaccination in Africa—no hesitancy without access Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29
No Abstract
-
Reinvigorating malaria control in Africa Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Vijay Shankar Balakrishnan
No Abstract
-
Raw milk, bird flu, and the politicisation of public health Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Cahal McQuillan
No Abstract
-
WHO reports gaps in global IPC programmes Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Timothy Jesudason
No Abstract
-
Increase in zoonotic diseases in Europe Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Sanjeet Bagcchi
No Abstract
-
-
Infectious disease surveillance update Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Cahal McQuillan
Section snippets Hepatitis A in SlovakiaOn Dec 19, 2024, the Regional Public Health Office (RUVZ) in Bratislava, Slovakia, reported an increase in the number of hepatitis A cases in all districts of the Bratislava region. According to the RUVZ, 73 cases of hepatitis A were recorded between Jan 1 and Dec 19, 2024, with 24 cases recorded in Dec 1–19 alone. The RUVZ state that vaccination is the most
-
Research in brief Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Priya Venkatesan
Section snippets Bedaquiline monotherapy for leprosyMonotherapy with bedaquiline, a diarylquinoline used to treat pulmonary multidrug-resistant tuberculosis, is efficacious in patients with multibacillary leprosy, suggests a phase 2, open-label study in Brazil. Nine adult patients with previously untreated leprosy consisting of at least six skin lesions received oral bedaquiline 200 mg once daily for
-
Adriaan Willem Sturm Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Sanjeet Bagcchi
Download: Download high-res image (52KB) Download: Download full-size image
-
Patrick de Marie Katoto—championing African public health Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Tony Kirby
No Abstract
-
Thyroid abscess caused by mucormycosis in a child with acute lymphoblastic leukaemia Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-29 Xu Yang, Yufeng Liang, Huiying Wu, Xiaohong Zhang
Section snippets ContributorsXY: conceptualisation, investigation, project administration, validation, visualisation, writing of the original draft, and review and editing. YL and HW: investigation, resources, validation, and review and editing. XZ: conceptualisation, investigation, methodology, project administration, resources, validation, supervision, review and editing. All authors had full access
-
Correction to Lancet Infect Dis 2025; 25: e11–12 Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-28
Colavita F, Carletti F, D'Abramo A, Nicastri E, Maggi F. Prolonged detection of Oropouche virus RNA in whole blood samples. Lancet Infect Dis 2025; 25: e11–12—In this Correspondence, the affiliation for all authors should have read “National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome 00149, Italy”. This correction has been made as of Jan 28, 2025.
-
Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1 Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-28 Jingyi Liu, Yuanling Yu, Sijie Yang, Fanchong Jian, Weiliang Song, Lingling Yu, Fei Shao, Yunlong Cao
No Abstract
-
HIV and rights for queer communities in Ghana Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-27 Henrietta Dunsmuir
No Abstract
-
Beyond an outbreak: no security without access to healthcare Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-27 Lucy Mae Spurgeon
No Abstract
-
Communities and tuberculosis control Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-24 Lauren Southwell
No Abstract
-
Correction to Lancet Infect Dis 2025; published online Jan 10. https://doi.org/10.1016/S1473-3099(24)00669-8 Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-24
Krolewiecki A, Stella S, Fleitas PE, et al. Albendazole–ivermectin co-formulation for the treatment of Trichuris trichiura and other soil-transmitted helminths: a randomised phase 2/3 trial. Lancet Infect Dis 2025; published online Jan 10. https://doi.org/10.1016/S1473-3099(24)00669-8—In the Funding section of the Summary of this Article, the name of the funder should have been the “European and Developing
-
The pioneer of mosquito control for yellow fever Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-24 Manjulika Das
No Abstract
-
Antiviral activity of tecovirimat against monkeypox virus clades 1a, 1b, 2a, and 2b Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-23 Jeanne Postal, Florence Guivel-Benhassine, Françoise Porrot, Quentin Grassin, Jack M Crook, Riccardo Vernuccio, Valérie Caro, Jessica Vanhomwegen, Pablo Guardado-Calvo, Etienne Simon-Lorière, Laurent Dacheux, Jean-Claude Manuguerra, Olivier Schwartz
No Abstract
-
Disseminated mpox in an immunocompromised patient in DR Congo: a call for a shift from disease-focused to person-centred outbreak response Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-22 Patrick Musole Bugeme, Patrick Kazuba Bugale, Joël Zigashane Mashauri, André Ishara Kapalata, Levi Bugwaja, Trust Faraja Mukika, Salomon Mashupe Shangula, Philémon Hodari Sebiyoyo, Daniel Buuma Barungu, Willy Kasi, Justin Bengehya, Patrick D M C Katoto, Esto Bahizire, Louise C Ivers, Pauline Vetter, Andrew S Azman, Espoir Bwenge Malembaka
No Abstract
-
Chronic intestinal spirochaetosis and Giardia lamblia infection mimicking eosinophilic enterocolitis Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-21 Maria Antonia De Francesco, Luca Paroni, Francesco Lanzarotto, Irene Zammarchi, Stefania Manenti, Anna Maria Mazzola, Vincenzo Villanacci
Human intestinal spirochaetosis is caused by the colonisation of the luminal membrane of the colon and rectum by anaerobic spirochaetes belonging to the genus Brachyspira. The common method used for its diagnosis is routine haematoxylin and eosin staining of colonic and rectal biopsy samples. The clinical spectrum of human intestinal spirochaetosis is heterogeneous, ranging from asymptomatic colonisation
-
Vaccine-derived poliovirus type 3 emergence in Guinea, 2024 Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-20 Martin Faye, Ndack Ndiaye, Etienne Kouame Kouadjo, Seydou Albert Camara, Sekou Solano, Ousmane Kébé, Niouma Nestor, Balkissa Modibo, Daman Keita, Bangaly Diakité, Kankou Sidibé, Moctar Kandé, Dadja Essoya Landoh, Mohamed Sylla, Sadou Sow, Annick Dosseh, Julius Ebua Chia, Ousmane Diop, Abdourahmane Sow, Ndongo Dia, Jean Marie Kipela
No Abstract
-
RSV vaccines: an elixir for healthy ageing? Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-20 Harish Nair, Thomas Williams
No Abstract
-
Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-20 Kristina L Bajema, Lei Yan, Yuli Li, Stephanie Argraves, Nallakkandi Rajeevan, Alexandra Fox, Robert Vergun, Kristin Berry, David Bui, Yuan Huang, Hung-Mo Lin, Denise M Hynes, Cynthia Lucero-Obusan, Patricia Schirmer, Francesca Cunningham, Grant D Huang, Mihaela Aslan, George N Ioannou
BackgroundNew respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older. Information on the real-world effectiveness of these vaccines is needed. MethodsWe used electronic health records in the Veterans Health Administration to emulate a target trial comparing a single dose of a recombinant
-
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00665-0 Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-17
Bennett JC, Deloria Knoll M, Kagucia EW, et al. Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00665-0—The appendices and collaborator list of this Article have been corrected as of Jan
-
Syphilitic bi-valvular endocarditis and myocarditis: modern tools applied to long-forgotten complications of a re-emerging disease Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-17 Louiselle LeBlanc, Dalila Touati, Simon Lévesque, Sofia Marouan, Claude Fortin, Jacques Pépin, Camilo Maya, Catherine Bourque
The incidence of syphilis has increased steadily over the past 25 years. Undiagnosed cases have presumably increased in the same proportions, and rare complications are at particularly high risk of being unrecognised. A previously healthy 60-year-old man presented with rapidly progressive heart failure and severe aortic and mitral valve insufficiency, with direct valvular destruction and preservation
-
A framework towards implementation of sequencing for antimicrobial-resistant and other health-care-associated pathogens Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-17 Alison Laufer Halpin, Amy J Mathers, Timothy R Walsh, Walter Zingg, Iruka N Okeke, L Clifford McDonald, Christopher A Elkins, Stephan Harbarth, Sharon J Peacock, Arjun Srinivasan, Michael Bell, Didier Pittet, Denise Cardo
Antimicrobial resistance continues to be a growing threat globally, specifically in health-care settings in which antimicrobial-resistant pathogens cause a substantial proportion of health-care-associated infections (HAIs). Next-generation sequencing (NGS) and the analysis of the data produced therein (ie, bioinformatics) represent an opportunity to enhance our capacity to address these threats. The
-
Correction to Lancet Infect Dis 2024; published online Oct 23. https://doi.org/10.1016/S1473-3099(24)00527-9 Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-16
Macià D, Campo JJ, Jairoce C, et al. The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial. Lancet Infect Dis 2024; published online Oct 23. https://doi.org/10.1016/S1473-3099(24)00527-9—In the table of this
-
Effectiveness of sulfadoxine–pyrimethamine plus amodiaquine and dihydroartemisinin–piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-15 Anthony Nuwa, Kevin Baker, Richard Kajubi, Chukwudi A Nnaji, Katherine Theiss-Nyland, Musa Odongo, Tonny Kyagulanyi, Jane Nabakooza, David Salandini, Victor Asua, Maureen Nakirunda, Christian Rassi, Damian Rutazaana, Richard Achuma, Patrick Sagaki, John Baptist Bwanika, Godfrey Magumba, Adoke Yeka, Sam Nsobya, Moses R Kamya, Jimmy Opigo
BackgroundSeasonal malaria chemoprevention (SMC) with sulfadoxine–pyrimethamine combined with amodiaquine (SPAQ) effectively protects eligible children from malaria in areas of high and seasonal transmission. However, concerns about parasite resistance to sulfadoxine–pyrimethamine in East and Southern Africa necessitate evaluating alternative drug regimens. This study assessed the effectiveness of
-
Expanding seasonal malaria chemoprevention beyond the Sahel region Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-15 Feiko O ter Kuile
No Abstract
-
Interim analysis of SARS-CoV-2 vaccine NVX-CoV2601 as a heterologous booster dose Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-14 Pragya D Yadav, Deepak Y Patil
No Abstract
-
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-14 Katia Alves, Karen Kotloff, R Scott McClelland, Alex Kouassi, Joyce S Plested, Raj Kalkeri, MingZhu Zhu, Shane Cloney-Clark, Zhaohui Cai, Katherine Smith, Muneer Kaba, Joy Nelson, E Adrianne Hammershaimb, Raburn M Mallory, Fernando Noriega
BackgroundAuthorities globally recommended a monovalent omicron XBB.1.5-based COVID-19 vaccine for the 2023–24 season. The Novavax COVID-19 vaccine, NVX-CoV2601, contains XBB.1.5 recombinant spike protein, based on an authorised prototype vaccine (NVX-CoV2373) technology. We aimed to determine whether a single dose of NVX-CoV2601 versus NVX-CoV2373 (from a previous study [2019nCoV-311 part 2]) produced
-
Quantifying Plasmodium vivax radical cure efficacy: a modelling study integrating clinical trial data and transmission dynamics Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-13 Constanze Ciavarella, Chris Drakeley, Ric N Price, Ivo Mueller, Michael White
BackgroundPlasmodium vivax forms dormant liver stages (hypnozoites) that can reactivate weeks to months after primary infection. Radical cure requires a combination of antimalarial drugs to kill both the blood-stage and liver-stage parasites. Hypnozoiticidal efficacy of the liver-stage drugs primaquine and tafenoquine cannot be estimated directly because hypnozoites are undetectable. We aimed to estimate
-
Efficacy of 8-aminoquinolines for Plasmodium vivax malaria radical cure: only one part of the problem Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-13 Marcus Lacerda, Márcio Cortez
No Abstract
-
Albendazole and ivermectin co-formulation for soil-transmitted helminthiases Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-10 Dora Buonfrate
No Abstract
-
Effect of mass drug administration on malaria incidence in southeast Senegal during 2020–22: a two-arm, open-label, cluster-randomised controlled trial Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-09 El-hadji Konko Ciré Ba, Michelle E Roh, Abdoulaye Diallo, Tidiane Gadiaga, Amadou Seck, Sylla Thiam, Ari Fogelson, Seynabou Gaye, Ibrahima Diallo, Aminata Colle Lo, Elhadji Diouf, Oumar Gallo Ba, Alioune Badara Gueye, Xue Wu, Paul Milligan, Tabitha Kibuka, Moustapha Hama, Erin Eckert, Julie Thwing, Adam Bennett, Jean Louis Ndiaye
BackgroundIn Africa, the scale-up of malaria-control interventions has reduced malaria burden, but progress towards elimination has stalled. Mass drug administration (MDA) is promising as a transmission-reducing strategy, but evidence from low-to-moderate transmission settings is needed. We aimed to assess the safety, coverage, and effect of three cycles of MDA with dihydroartemisinin–piperaquine plus
-
Another antimalarial mass drug administration? Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-09 Lorenz von Seidlein
No Abstract
-
Albendazole–ivermectin co-formulation for the treatment of Trichuris trichiura and other soil-transmitted helminths: a randomised phase 2/3 trial Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-10 Alejandro Krolewiecki MD, Stella Kepha PhD, Pedro E Fleitas PhD, Lisette van Lieshout PhD, Woyneshet Gelaye PhD, Augusto Messa Jr MSc, Javier Gandasegui PhD, Jaime Algorta MD, Valdemiro Novela BSc, Áuria de Jesus MD, Martin Rono PhD, Dawit Degarege MD, Dereje Bedane MD, Jusper Mwahanje MD, Inácio Mandomando PhD, Charles Mwandawiro PhD, Wendemagegn Enbiale MD, José Muñoz MD, Stopping Transmission of
Treatments for soil-transmitted helminthiases face challenges, especially in addressing Trichuris trichiura. Combination regimens, particularly of ivermectin and albendazole, are promising. We aimed to assess the safety, efficacy, and palatability of a combination tablet for the treatment of T trichiura, hookworm, and Strongyloides stercoralis infections among school-aged children in Ethiopia, Kenya
-
Treating a feverish planet: The Dengue Alliance Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-10 Vijay Shankar Balakrishnan
No Abstract
-
Engaging pose and gaze in global health research Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-10 Bipin Adhikari, Shiva Raj Mishra
No Abstract
-
Bees and Anopheles Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-10 Phoebe Ashley-Norman
No Abstract
-
The effectiveness of two doses of recombinant hepatitis E vaccine in response to an outbreak in Bentiu, South Sudan: a case–control and bias indicator study Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-08 Robin C Nesbitt, Vincent Kinya Asilaza, Catia Alvarez, Priscillah Gitahi, Patrick Nkemenang, Jetske Duncker, Melat Haile, Primitive Gakima, Joseph F Wamala, Fredrick Beden Loro, Aybüke Koyuncu, Duol Biem, Manuel Albela, Monica Rull, Etienne Gignoux, John Rumunu, Isabella Eckerle, Iza Ciglenecki, Andrew S Azman
BackgroundHepatitis E virus (HEV) is a leading cause of acute viral hepatitis, particularly in Asia and Africa, where HEV genotypes 1 and 2 are prevalent. Although a recombinant vaccine, Hecolin, is available, it has not been used to control outbreaks. The licensed three-dose regimen might pose challenges for it to be an impactful outbreak control tool. Our study aimed to estimate the effectiveness
-
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluster-randomised trial Lancet Infect Dis (IF 36.4) Pub Date : 2025-01-08 Matthew E Coldiron, Issaka Soumana, Elisabeth Baudin, Céline Langendorf, Corinne Mamiafo Tchoula, Souleymane Brah, Angela Karani, Katherine E Gallagher, E Wangeci Kagucia, J Anthony G Scott, Rebecca F Grais
BackgroundIn settings with low pneumococcal conjugate vaccine (PCV) coverage, multi-age cohort mass campaigns could increase population immunity, and fractional dosing could increase affordability. We aimed to evaluate the effect of mass campaigns on nasopharyngeal pneumococcal carriage of Pneumosil (PCV10) in children aged 1–9 years in Niger. MethodsIn this three-arm, open-label, cluster-randomised